Annotation Detail for SLC17A7
Basic Information
Top
| Gene Symbol: | SLC17A7 ( BNPI,VGLUT1 ) |
|---|
| Gene Full Name: | solute carrier family 17 (sodium-dependent inorganic phosphate cotransporter), member 7 |
|---|
| Band: | 19q13.33 |
|---|
| Quick Links | Entrez ID:57030; OMIM: 605208; Uniprot ID:VGLU1_HUMAN; ENSEMBL ID: ENSG00000104888; HGNC ID: 16704 |
|---|
| Relate to Another Database: |
SFARIGene;
denovo-db |
| Pathway ID | Pathway Name |
|---|
| Synaptic Transmission |
| Transmembrane transport of small molecules |
| Amino acid and oligopeptide SLC transporters |
| Pathway ID | Pathway Name |
|---|
| P00039 | Metabotropic glutamate receptor group III pathway |
| Pathway ID | Pathway Name |
|---|
| 500150 | Glutamate Neurotransmitter Release Cycle |
| Desease ID | Desease Name |
|---|
| 2069 | Schizophrenia |
| Chemical ID |
Chemical Name |
Interaction |
Interaction Action |
Publication |
|---|
| D000643 |
Ammonium Chloride |
Ammonium Chloride affects the expression of SLC17A7 mRNA | affects expression | 16483693
|
| D003024 |
Clozapine |
Clozapine results in increased expression of SLC17A7 mRNA | increases expression | 16111724
|
| D003024 |
Clozapine |
Clozapine results in increased expression of SLC17A7 protein | increases expression | 16111724
|
| D003891 |
Desipramine |
Desipramine results in increased expression of SLC17A7 mRNA | increases expression | 16111724
|
| D003891 |
Desipramine |
Desipramine results in increased expression of SLC17A7 protein | increases expression | 16111724
|
| D005473 |
Fluoxetine |
Fluoxetine results in increased expression of SLC17A7 mRNA | increases expression | 16111724
|
| D005473 |
Fluoxetine |
Fluoxetine results in increased expression of SLC17A7 protein | increases expression | 16111724
|
| D008094 |
Lithium |
Lithium results in increased expression of SLC17A7 mRNA | increases expression | 16111724
|
| D008094 |
Lithium |
Lithium results in increased expression of SLC17A7 protein | increases expression | 16111724
|
| D010710 |
Phosphates |
SLC17A7 protein results in increased transport of [Sodium co-treated with Phosphates] | affects cotreatment|increases transport | 10962014
|
| D020849 |
Raloxifene |
Raloxifene results in decreased expression of SLC17A7 mRNA | decreases expression | 15849065
|
| D012964 |
Sodium |
SLC17A7 protein results in increased transport of [Sodium co-treated with Phosphates] | affects cotreatment|increases transport | 10962014
|
| Disease ID |
Disease Name |
Direct Evidence |
Inference Chemical Name |
Inference Score |
Publication |
|---|
| MESH:D000138 |
Acidosis |
|
Ammonium Chloride |
3.90 | 18287403 |
| MESH:D000380 |
Agranulocytosis |
|
Clozapine |
5.36 | 14617031 12649775 16160616 |
| MESH:D000419 |
Albuminuria |
|
Raloxifene |
4.88 | 17308373 17451421 |
| MESH:D000544 |
Alzheimer Disease |
|
Lithium |
4.91 | 19621015 |
| MESH:D000544 |
Alzheimer Disease |
|
Raloxifene |
4.91 | 15800139 |
| MESH:D001008 |
Anxiety Disorders |
|
Fluoxetine |
5.12 | 18083778 |
| MESH:D001321 |
Autistic Disorder |
|
Fluoxetine |
3.35 | 18775368 19232924 |
| MESH:D001714 |
Bipolar Disorder |
|
Lithium |
4.43 | 20046352 19153942 20338123 17594078 |
| MESH:D001930 |
Brain Injuries |
|
Raloxifene |
4.78 | 16580743 |
| MESH:D001943 |
Breast Neoplasms |
|
Raloxifene |
2.64 | 17595753 17261762 17242785 16912660 16837676 17049068 15775269 17952589 15572757 15758505 17893378 17440819 |
| MESH:D002295 |
Carcinoma, Transitional Cell |
|
Raloxifene |
4.30 | 17572228 |
| MESH:D002318 |
Cardiovascular Diseases |
|
Raloxifene |
3.60 | 15775269 |
| MESH:D003072 |
Cognition Disorders |
|
Clozapine |
12.73 | 17123785 |
| MESH:D003072 |
Cognition Disorders |
|
Raloxifene |
12.73 | 15800139 |
| MESH:D007644 |
Darier Disease |
|
Lithium |
6.25 | 20338123 |
| MESH:D003866 |
Depressive Disorder |
|
Desipramine |
9.47 | 15014590 3690436 |
| MESH:D003866 |
Depressive Disorder |
|
Fluoxetine |
9.47 | 15014590 |
| MESH:D003865 |
Depressive Disorder, Major |
|
Raloxifene |
4.38 | 17474826 |
| MESH:D018500 |
Diabetes Insipidus, Nephrogenic |
|
Lithium |
6.05 | 19244398 |
| MESH:D003924 |
Diabetes Mellitus, Type 2 |
|
Clozapine |
3.02 | 16402076 |
| MESH:D003928 |
Diabetic Nephropathies |
|
Raloxifene |
4.15 | 17308373 15920148 17451421 |
| MESH:D006970 |
Disorders of Excessive Somnolence |
|
Clozapine |
5.93 | 15331141 |
| MESH:D004409 |
Dyskinesia, Drug-Induced |
|
Desipramine |
6.56 | 3690436 |
| MESH:D050171 |
Dyslipidemias |
|
Clozapine |
4.35 | 16402076 |
| MESH:D004487 |
Edema |
|
Fluoxetine |
8.40 | 12798668 |
| MESH:D004487 |
Edema |
|
Raloxifene |
8.40 | 15860553 |
| MESH:D004681 |
Encephalomyelitis, Autoimmune, Experimental |
|
Raloxifene |
4.28 | 15845917 |
| MESH:D005234 |
Fatty Liver |
|
Raloxifene |
3.86 | 17473493 |
| MESH:D006330 |
Heart Defects, Congenital |
|
Lithium |
4.33 | 19638421 |
| MESH:D006331 |
Heart Diseases |
|
Raloxifene |
3.69 | 11110106 |
| MESH:D019584 |
Hot Flashes |
|
Fluoxetine |
5.69 | 14716179 |
| MESH:D006948 |
Hyperkinesis |
|
Clozapine |
5.25 | 16046005 |
| MESH:D006973 |
Hypertension |
|
Raloxifene |
2.94 | 15787275 17577099 |
| MESH:D007249 |
Inflammation |
|
Fluoxetine |
3.96 | 12798668 |
| MESH:D007889 |
Leiomyoma |
|
Raloxifene |
4.76 | 16973256 |
| MESH:D008064 |
Lipidoses |
|
Clozapine |
9.19 | 17567588 |
| MESH:D008064 |
Lipidoses |
|
Fluoxetine |
9.19 | 15342952 17567588 |
| MESH:D001523 |
Mental Disorders |
|
Clozapine |
21.97 | 16856516 |
| MESH:D001523 |
Mental Disorders |
|
Desipramine |
21.97 | 16856516 |
| MESH:D001523 |
Mental Disorders |
|
Fluoxetine |
21.97 | 16856516 |
| MESH:D001523 |
Mental Disorders |
|
Phosphates |
21.97 | 12686366 |
| MESH:D024821 |
Metabolic Syndrome X |
|
Clozapine |
4.61 | 19142101 |
| MESH:D018200 |
Mixed Tumor, Mullerian |
|
Raloxifene |
5.93 | 15863610 |
| MESH:D009101 |
Multiple Myeloma |
|
Raloxifene |
3.60 | 16497877 |
| MESH:D009203 |
Myocardial Infarction |
|
Lithium |
4.01 | 16288908 |
| MESH:D009207 |
Myoclonus |
|
Fluoxetine |
6.21 | 8041377 |
| MESH:D009232 |
Myxoma |
|
Raloxifene |
5.93 | 16343187 |
| MESH:D009765 |
Obesity |
|
Clozapine |
3.06 | 19142110 18515891 |
| MESH:D009771 |
Obsessive-Compulsive Disorder |
|
Fluoxetine |
5.69 | 20418887 |
| MESH:D010024 |
Osteoporosis |
|
Raloxifene |
3.53 | 19059307 15775268 17882678 |
| MESH:D015663 |
Osteoporosis, Postmenopausal |
|
Raloxifene |
4.49 | 15579764 15758505 17823083 17893378 |
| MESH:D010146 |
Pain |
|
Fluoxetine |
4.53 | 12798668 |
| MESH:D010300 |
Parkinson Disease |
|
Desipramine |
4.45 | 10965161 |
| MESH:D020774 |
Pick Disease of the Brain |
|
Fluoxetine |
6.31 | 8041377 |
| MESH:D011471 |
Prostatic Neoplasms |
|
Raloxifene |
3.57 | 15731164 16220300 16536755 |
| MESH:D011618 |
Psychotic Disorders |
|
Clozapine |
4.35 | 15331141 |
| MESH:D011693 |
Purpura |
|
Raloxifene |
5.93 | 15770314 |
| MESH:D012559 |
Schizophrenia |
|
Clozapine |
2.76 | 19369910 20168265 17123785 17667964 11763009 11151749 20521326 18806925 18855531 17726453 20452607 20521320 20107430 16141801 20580759 |
| MESH:D012640 |
Seizures |
|
Lithium |
4.14 | 19660546 |
| MESH:D020230 |
Serotonin Syndrome |
|
Fluoxetine |
6.27 | 8704074 |
| MESH:D013226 |
Status Epilepticus |
|
Lithium |
6.16 | 19570321 19951488 19430551 |
| MESH:D020521 |
Stroke |
|
Raloxifene |
4.01 | 16837676 |
| MESH:D013978 |
Tibial Fractures |
|
Raloxifene |
5.58 | 19048282 |
| MESH:D001749 |
Urinary Bladder Neoplasms |
|
Raloxifene |
2.89 | 17572228 |
| MESH:D054556 |
Venous Thromboembolism |
|
Raloxifene |
5.58 | 16837676 |
| MESH:D014846 |
Vulvar Neoplasms |
|
Raloxifene |
5.93 | 16343187 |
| MESH:D015430 |
Weight Gain |
|
Clozapine |
4.68 | 20107430 17502770 20564506 20521320 16141801 16402076 |
| MESH:D015431 |
Weight Loss |
|
Clozapine |
5.41 | 17933447 |
PharmGKB Accession:PA423
| Releated disease ID |
Related disease Name |
| PA447199 | Bipolar Disorder |
| PA447216 | Schizophrenia |
Drug Bank